Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of irinotecan + bevacizumab around temozolomide chemoradiotherapy for unresectable glioblastoma
2008-002775-28Phase 2Active
- Sponsor
- Centre Georges-François Leclerc
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, bevacizumab and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Centre Georges-François Leclerc. Primary endpoint: Progression-free survival at 6 months. Started Oct 2008; status: active.
02
Drugs
irinotecanbevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-002775-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002775-28.